Showing 2022 companies
Company Headquarters: Texas, United States Founded: 1999 Workforce: ~63,000 Company Working: ExxonMobil Corporation (ExxonMobil) is an American multinational oil & gas corporation. It performs crude oil refinement, makes lube base stocks and finished lubricants, transports, trades, and sells petroleum products. Additionally, the business produces and sells a wide range of specialty goods in addition to commodity petrochemicals such as olefins, aromatics, polyethylene, and polypropylene plastics. High-performance fuels and lubricant products made by ExxonMobil power global transportation, increase efficiency and lower the entire life-cycle emissions of our clients. It runs through a network of production facilities, transit hubs, and distribution facilities. North America, Latin America, Asia Pacific, Europe, the Middle East, and Africa are all operational regions for the company.
Ashland is a focused, mid-cap additives and specialty ingredients company built around two chemistry franchises, cellulose ethers and vinyl pyrrolidone polymers, which together accounted for roughly 64% of FY2025 sales. After a decade of divestitures (Valvoline, composites, adhesives, nutraceuticals, Avoca) it is now a consumer-leaning portfolio. Life Sciences (pharmaceutical excipients, injectables, tablet coatings) and Personal Care (biofunctional actives, microbial protection, hair, skin and oral care polymers) generate most of the profit at adjusted EBITDA margins near 30%. A cyclical Specialty Additives business tied to architectural coatings and a small, trough-level butanediol Intermediates unit make up the rest. FY2025 sales were USD 1,824 M with adjusted EBITDA of USD 401 M. The company enters FY2027 with strong pharma volumes, a self-inflicted manufacturing problem at its Hopewell HEC plant, sub-investment-grade ratings one notch lower than a year ago, and an activist-influenced board weighing capital allocation and, potentially, a sale. --- ### The company's own description In its FY2025 annual report Ashland describes itself as a global additives and specialty ingredients company with a deliberate sustainability orientation. It serves consumer and industrial markets including architectural coatings, construction, energy, food and beverage, personal care and pharmaceuticals, with about 2,900 employees and customers in more than 100 countries (10-K FY2025, Item 1). Its stated purpose is to "responsibly solve for a better world" (Proxy 2026). Earnings releases add that the company holds leadership positions in pharmaceuticals, personal care and architectural coatings (PR Q3 FY2026). ### Independent characterization | Product family | Share of FY2025 consolidated sales | Share of segment sales | Source | |---|---|---|---| | Cellulosics (HEC, HPC, HPMC, MC, CMC, EC) | 39% | Life Sciences 43%; Personal Care 20%; Specialty Additives 62% | 10-K FY2025 Item 1 | | Polyvinylpyrrolidones (PVP and derivatives) | 25% | Life Sciences 42%; Personal Care 23%; Specialty Additives 7% | 10-K FY2025 Item 1 | Ashland is best understood as a polymer-chemistry platform, not a diversified chemical company. Two product families dominate: The remaining third or so of sales comprises biofunctional actives, preservatives, guar and other natural derivatives, synthetic associative thickeners, foam-control agents, surfactants, and merchant butanediol and derivatives. **Business model.** Ashland makes functional ingredients that are a small share of a customer's formulation cost but determine performance: tablet disintegration, drug release, paint rheology, hair hold, preservative efficacy. Customers qualify these ingredients into regulated or specification-driven formulations, so switching costs are high and qualification cycles long, particularly in pharma. The model depends on application know-how and technical service as much as molecule manufacturing. **Revenue model.** Revenue is essentially 100% product sales recognized at a point in time. There is no material service, subscription or licensing revenue disclosed. Distribution is direct to large multinationals plus distributors for the fragmented tail (IMCD for US personal and home care from April 2026; WACKER cyclodextrins distributed by Ashland; Azelis affiliate Catalite in Thailand). Pricing is negotiated; list prices are not disclosed. In March 2026 the company announced portfolio-wide price increases in response to energy and raw-material volatility (IR, 23 Mar 2026). **Value chain position.** Ashland sits mid-chain. Upstream it buys wood pulp and cotton linters (cellulose), acetylene-chain feedstocks, ethylene oxide, guar, clary sage (until the Avoca sale) and other naturals. It is back-integrated into butanediol (Lima, Ohio), which feeds its own pyrrolidone chain; captive BDO is transferred at market-based prices (PR Q4 FY2025). Downstream it sells to formulators, not consumers. **Customer types.** Pharmaceutical and generic drug manufacturers, nutrition and beverage producers, multinational and independent personal care brands, paint and coatings manufacturers, construction-materials producers, oilfield service companies, and industrial users of BDO derivatives (engineering polymers, electronics, battery manufacturing). Reuters reporting on the Ancora campaign names L'Oréal, Estée Lauder and Pfizer among customers. Merck & Co., where director Sanat Chattopadhyay is an executive, paid Ashland about USD 9.7 M in FY2025 (Proxy 2026). **End-market mix (FY2025 sales).** Life Sciences 35%, Personal Care 32%, Specialty Additives 28%, Intermediates 7% before intersegment eliminations (PR Q4 FY2025; Analyst). **Seasonality.** Demand is typically stronger in warmer months. The fiscal first quarter (October to December) is the seasonal low (10-K FY2025; PR Q1 FY2026).
Unlock Verified Contacts
Access verified employee contacts
Decision-maker information to support your sales, lead generation, and business development. 5 users, 5,500 credits a month with rollover, and one credit per contact email.
Powering the world's best teams.
From next-gen startups to established enterprises.
Trusted by forward-thinking businesses
for data-driven intelligence